World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
82
Citations
23613
World Ranking
1508
National Ranking
128

Martin J. Glennie publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Martin J. Glennie sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 230 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Martin J. Glennie D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Martin J. Glennie sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 82 D-Index — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Martin J. Glennie is affiliated with the University of Southampton in the United Kingdom. Their research primarily focuses on immunology and microbiology, with significant contributions to medicine as well. The scientist's work spans several subfields including immunology, radiology, nuclear medicine and imaging, molecular biology, oncology, and cancer research.

The research topics that Martin J. Glennie has extensively investigated include monoclonal and polyclonal antibodies research, T-cell and B-cell immunology, immune cell function and interaction, CAR-T cell therapy research, galectins and cancer biology, immunotherapy and immune responses, and glycosylation and glycoproteins research.

Martin J. Glennie has contributed to various academic journals, with frequent publications appearing in:

  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature
  • Cancer Cell
  • JCI Insight

Recent notable papers authored or co-authored by Martin J. Glennie include:

  • "Reducing affinity as a strategy to boost immunomodulatory antibody agonism" (2023), published in Nature
  • "Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity" (2020), published in Cancer Cell
  • "LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation" (2020), published in JCI Insight
  • "TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity" (2021), published in Communications Biology
  • "Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility" (2022), published in Science Immunology

Frequent co-authors collaborating with Martin J. Glennie include:

  • Mark S. Cragg
  • H. T. Claude Chan
  • C. Ian Mockridge
  • Tatyana Inzhelevskaya
  • Ivo Tews

Best Publications

  • Guidelines for the welfare and use of animals in cancer research

    P Workman;E O Aboagye;F Balkwill;A Balmain

  • Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

    Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel

  • The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

    Jessica L. Teeling;Wendy J.M. Mackus;Luus J.J.M. Wiegman;Jeroen H.N. van den Brakel

  • Immunostimulatory monoclonal antibodies for cancer therapy

    Ignatio Melero;Sandra Hervas-Stubbs;Martin Glennie;Drew M. Pardoll

  • Human monoclonal antibodies against cd20

    Jessica Woodmill Cottage Teeling;Sigrid Ruuls;Martin Glennie;Jan G. J. Van De Winkel

  • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan

  • Mechanisms of killing by anti-CD20 monoclonal antibodies.

    Martin J. Glennie;Ruth R. French;Mark S. Cragg;Ronald P. Taylor

  • Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.

    Mark S. Cragg;Martin J. Glennie

  • CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

    R.R. French;H.T.C. Chan;A.L. Tutt;M.J. Glennie

  • The biology of CD20 and its potential as a target for mAb therapy.

    Mark S. Cragg;Claire A. Walshe;Andrey O. Ivanov;Martin J. Glennie

  • Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.

    A Tutt;G T Stevenson;M J Glennie

  • Clinical trials of antibody therapy.

    Martin J Glennie;Peter W.M Johnson

  • Agonistic CD40 Antibodies and Cancer Therapy

    Robert H. Vonderheide;Martin J. Glennie

  • Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

    M J Glennie;H M McBride;A T Worth;G T Stevenson

  • Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    Stephen A. Beers;Ruth R. French;H. T. Claude Chan;Sean H. Lim

  • Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

    Waleed Alduaij;Andrei Ivanov;Jamie Honeychurch;Eleanor J Cheadle

  • The mechanisms of action of rituximab in the elimination of tumor cells

    Peter W M Johnson;Martin J Glennie

  • Anti-CD20 monoclonal antibodies: historical and future perspectives

    Sean H. Lim;Stephen A. Beers;Ruth R. French;Peter W.M. Johnson

  • Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

    Sean H Lim;Andrew T Vaughan;Margaret Ashton-Key;Emily L Williams

  • Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.

    J H Ellis;K A Barber;A Tutt;C Hale

Frequent Co-Authors

Mark S. Cragg
Mark S. Cragg University of Southampton
Peter Johnson
Peter Johnson University of Southampton
Aymen Al-Shamkhani
Aymen Al-Shamkhani University of Southampton
Freda K. Stevenson
Freda K. Stevenson University of Southampton
Ole Baadsgaard
Ole Baadsgaard Genmab (United States)
Jan G. J. van de Winkel
Jan G. J. van de Winkel Genmab (United States)
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center
Andrew J. T. George
Andrew J. T. George Imperial College London
Paul W. H. I. Parren
Paul W. H. I. Parren Leiden University Medical Center
Tibor Keler
Tibor Keler Bristol-Myers Squibb (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to a variety of healthcare career paths that complement your scientific knowledge. For those interested in advancing clinical skills, exploring programs like the 12-month accelerated nursing programs can provide a fast track into nursing roles while building on your background in health sciences.

If you’re looking for entry-level clinical experience, consider options with more flexible admission criteria such as lpn programs with easiest admission requirements. These programs can serve as a stepping stone to higher nursing degrees or healthcare certifications.

For those aiming to become advanced practice nurses, degrees like the easiest fnp program offer a pathway into Family Nurse Practitioner roles. These programs are designed to be accessible while providing comprehensive clinical training.

Specializing further in mental health, students and professionals can explore pmhnp programs online with best clinical placement, which highlight excellent opportunities for quality clinical placements and flexible online learning.

Overall, these related online degrees provide diverse opportunities to build a rewarding healthcare career aligned with your immunology expertise.

Best Scientists Citing Martin J. Glennie

Trending Scientists

Recently Published Articles